Riquent Could Be Approved Based On Ongoing Confirmatory Study, La Jolla Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “approvable” letter for lupus therapy Riquent cites need for additional study with endpoint of clinical benefit, such as time to renal flare. La Jolla had attempted to get accelerated approval using surrogate endpoint of change in antibodies to double-stranded DNA.
You may also be interested in...
La Jolla Submits Riquent Application For Lupus In EU
The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.
La Jolla Submits Riquent Application For Lupus In EU
The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.
La Jolla Proceeds With Additional Riquent Dosing Study
High doses of lupus agent appear to be "well-tolerated" in healthy volunteers, firm says. Dose-response data are being collected in response to FDA's "approvable" letter. La Jolla plans to add the information to ongoing pivotal trial.